Overexpression of Y-box binding protein-1 in cervical cancer and its association with the pathological response rate to chemoradiotherapy

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1992-1997

  Zhang, Y ^a   Reng, S R ^a   Wang, L ^a   Lu, L ^a   Zhao, Z H ^a   Zhang, Z K ^b   Feng, X D ^b   Ding, X D ^b   Wang, J ^a   Feng, G ^a   Dai, T Z ^a   Pu, J ^a   Du, X B ^a  

^a MIANYANG CENTRAL HOSPITAL   (China)

^b Guangzhou Kingmed Center for Clinical Laboratory   (China)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Chemoradiosensitivity; Immunohistochemical; Y box binding protein 1

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; Y BOX BINDING PROTEIN 1;

ARTICLE; CANCER PATIENT; CARCINOGENESIS; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; SCORING SYSTEM; TREATMENT RESPONSE; UTERINE CERVICITIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CHEMORADIOTHERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; UTERINE CERVICAL NEOPLASMS; UTERINE CERVICITIS; Y-BOX-BINDING PROTEIN 1;

EID: 84872772511     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0062-2     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-50.
3. Schoell WMJ, Janicek MR, Mirhashemi R. Epidemiology and biology of cervical cancer. Semin Surg Oncol. 1999;16:203-11.
4. Wan Fang, Miao X, Quraishi I, Kennedy V, Kim E, Creek KE, Pirisi L. Gene expression changes during HPV-mediated carcinogenesis: a comparison between an in vitro cell model and cervical cancer. Int J Cancer. 2008;123:32-40.
5. Narisawa-Saito M, Yoshimatsu Y, Ohno S, Yugawa T, Egawa N, Fujita M, Hirohashi S, Kiyono T. An in vitro multistep carcinogenesis model for human cervical cancer. Cancer Res. 2008;68:5699-705.
6. Petignat P, Roy M. Diagnosis and management of cervical cancer. BMJ. 2007;335:765-8.
7. Poujade O, Morice P, Rouzier R, Madelenat P, Lecuru F, Muray JM, Mathevet P, Alran S, Salmon RJ, Reyal F. Pathologic response rate after concomitant neo-adjuvant radiotherapy and chemotherapy for adenocarcinoma of the uterine cervix: a retrospective multicentric study. Int J Gynecol Cancer. 2010;20: 815-20.
8. Zhu H, Pei HP, Zeng S, Chen J, Shen LF, Zhong MZ, Yao RJ, Shen H. Profiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma. J Proteome Res. 2009;8:3969-76.
9. Tanaka T, Bai T, Yukawa K, Utsunomiya T, Umesaki N. Reduced radiosensitivity and increased CD40 expression in cyclophosphamide-resistant subclones established from human cervical squamous cell carcinoma cells. Oncol Rep. 2005;14: 941-8.
10. Gu C, Oyama T, Osaki T, Kohno K, Yasumoto K. Expression of Y box-binding protein 1 correlates with DNA topoisomerase II alpha and proliferating cell nuclear antigen expression in lung cancer. Anticancer Res. 2001;21:2357-62.
11. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, Yasumoto K, Sugimachi K, Kuwano M. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res. 2001;7:3151-5.
12. Faury D, Nantel A, Dunn SE, Guiot M-C, Haque T, Hauser P, Garami M, Bognár L, Hanzély Z, Liberski PP, Lopez-Aguilar E, Valera ET, Tone LG, Carret A-S, Del Maestro RF, Gleave M, Montes J-L, Pietsch T, Albrecht S, Jabado N. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007;25:1196-208.
13. Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, Park E, Shadeo A, Buys TPH, Lam W, Pugh T, Marra MA, Nielsen TO, Klinge U, Mertens PR, Aparicio S, Dunn SE. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer providing a potential target for therapy. Breast Cancer Res. 2007;9:R61.
14. Wu J, Lee C, Yokom D, Jiang H, Cheang MCU, Yorida E, Turbin D, Berquin IM, Mertens PR, Iftner T, Gilks B, Dunn SE. Disruption of the Y-box binding protein-1 (YB-1) results in suppression of the epidermal growth factor receptor and Her-2. Cancer Res. 2006;66:4872-9.
15. Oda Y, Ohishi Y, Saito T, Hinoshita E, Uchiumi T, Kinukawa N, Iwamoto Y, Kohno K, Kuwano M, Tsuneyoshi M. Nuclear expression of Y-box binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression and with poor prognosis in synovial sarcoma. J Pathol. 2003;199:251-8.
16. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Gleave ME, Nelson CC. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate. 2004;59:337-49.
17. Shibao K, Takano H, Nakayama Y, Okazaki K, Nagat N, Izumi H, Uchiumi T, Kuwano M, Kohno K, Itoh H. Enhanced coexpression of YB-1 and DNA topoisomerase II a genes in human colorectalcarcinomas. Int J Cancer. 1999;83:732-7.
18. Oda Y, Sakamoto A, Shinohara N, Ohga T, Uchiumi T, Kohno K, Tsuneyoshi M, Kuwano M, Iwamoto Y. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteocarcinoma. Clin Cancer Res. 1998;4:2273-7.
19. Bergmann S, Royer-Pokora B, Fietze E, Jürchott K, Hildebrandt B, Trost D, Leenders F, Claude JC, Theuring F, Bargou R, Dietel M, Royer HD. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res. 2005;10:4078-87.
20. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, K A, Yokomizo A, Naito S, Kohno K. Twist promotes tumor cell growth through YB-1 expression. Cancer Res. 2008;68:98-105.
21. Fujii T, Seki N, Namoto-Matsubayashi R, Takahashi H, Inoue Y, Toh U, Kage M, Shirouzu K. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res. 2008;68:8661-6.
22. Chatterjee M, Rancso C, Stühmer T, Eckstein N, Andrulis M, Gerecke C, Lorentz H, Royer HD, Bargou RC. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug. Blood. 2008;111:3714-22.
23. Berquin IM, Pang B, Dziubinski ML, Scott LM, Chen YQ, Nolan GP, Ethier SP. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene. 2005;24: 3177-86.
24. Basaki Y, Hosoi F, Oda Y, Fotovati A, Maruyama Y, Oie S, Ono M, Izumi H, Kohno K, Sakai K, Shimoyama T, Nishio K, Kuwano M. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene. 2007;26:2736-46.
25. Bargou RC, Jürchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dörken B, Royer HD. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsicMDR1 gene expression. NatMed. 1997;3:447-50.
26. Huang J, Tan PH, Li KB, Matsumoto K, Tsujimoto M, Bay BH. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. Int J Oncol. 2005;26:607-13.
27. Tay WL, Yip GWC, Tan PH, Matsumoto K, Yeo R, Ng TP, Kumar SD, Tsujimoto M, Bay BH. Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod Pathol. 2009;22: 282-90.
28. McCarty KS, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986;46: 4244-8.
29. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays. 2003;25:691-8.
30. Matsumoto K, Wolffe AP. Gene regulation by Y-box proteins: coupling control of transcription and translation. Trends Cell Biol. 1998;8:318-23.
31. Evdokimova V, Ruzanov P, Imataka H, Raught B, Svitkin Y, Ovchinnikov LP, Sonenberg N. The major mRNA-associated protein YB-1 is a potent 50 cap-dependent mRNA stabilizer. EMBO J. 2001;20:5491-502.
32. Skabkin MA, Kiselyova OI, Chernov KG, Sorokin AV, Dubrovin EV, Yaminsky IV, Vasiliev VD, Ovchinnikov LP. Structural organization of mRNA complexes with major core mRNP protein YB-1. Nucl Acids Res. 2004;32:5621-35.
33. Lasham A, Moloney S, Hale T, Homer C, Zhang YF, Murison JG, Braithwaite AW, Watson J. The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem. 2003;12:35516-23.
34. Chaudhary PM, Roninson LB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 1993;85:632-9.
35. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H, Kamura T, Tsuneyoshi M, Yasumoto K, Kohno K. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther. 2004;3:1485-92.
36. Ohga T, Uchiumi T, Makino Y, et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem. 1998;273:5997-6000.
37. Li Y, Wen ZS, Yang HX, Luo RZ, Zhang Y, Zhang MF, Wang X, Jia WH. High Expression of Y-Box-Binding Protein-1 is associated with poor survival in resectable esophageal squamous cell carcinoma. Ann Surg Oncol 2011 Jun 1. [Epub ahead of print].
38. Toulany M, Schickfluß TA, Eicheler W, Kehlbach R, Schittek B, Rodemann HP. Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation. Breast Cancer Res. 2011;13:R28.